Royalty Pharma

RPRX

Market cap $17.1B

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:

Royalty Pharma is reiterated as a Buy, supported by strong Q3 results, raised guidance, and disciplined capital deployment. The company trades at a notable discount to biopharma peers despite robust FCF, portfolio growth, and a diversified royalty-based business model. Platform model delivering diversified biopharma exposure, buybacks ongoing, and new deals to be priced in. Our buy is then confirmed.

Royalty Pharma plc ( RPRX ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Pablo Legorreta - Founder, Chairman of the Board & CEO Marshall Urist - Executive Vice President of Research & Investments Christopher Hite - Vice Chairman & Executive VP Terrance Coyne - Executive VP & CFO Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Hardik Parikh - JPMorgan Chase & Co, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Terence Flynn - Morgan Stanley, Research Division Michael Nedelcovych - TD Cowen, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to Royalty Pharma Third Quarter Earnings Conference Call.

Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Royalty Pharma (RPRX) came out with quarterly earnings of $1.17 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $1.04 per share a year ago.

Portfolio Receipts growth of 11% to $814 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $703 million Raised full year 2025 guidance: Portfolio Receipts expected to be $3,200 to $3,250 million NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. “We delivered strong third quarter 2025 results, raised our full year guidance and are on track to deliver another year of double-digit top-line growth,” said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer.

NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam's AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million. The royalty interest being sold stems from Blackstone's 2020 financing collaboration with Alnylam , in which Blackstone invested to support AMVUTTRA's pivotal Phase 3 HELIOS-B trial.

Investing in biotechnology often feels like navigating a minefield. A single failed clinical trial can decimate a stock, while a blockbuster approval can generate spectacular returns.

Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share.